A new acquisition
In 2018, BD acquired the US medical technology company Bard for $24 billion. Bard’s strong product portfolio and innovation pipeline increase BD’s opportunities in highgrowth clinical segments, especially peripheral vascular therapy, oncology and bio-surgery,” Mr Goette says. With this acquisition, almost 16,000 people have joined
the medical technology giant. The deal gives a glimpse of new opportunities to strengthen BD’s leading position in medication management and infection prevention. The company’s European headquarters now has over 250 employees. “The Canton of Vaud is the perfect fit for us with its extensive collaboration between universities and research companies, and access to a pool of highly skilled talent. Its central location in Europe, vastly developed and efficient infrastructure, multilingualism, along with a stable, convertible currency make the region a good choice for a company like ours.”